Technology evaluation: HPV vaccine (quadrivalent), Aventis Pasteur MSD/CSL.
CSL, licensee of UniQuest's HPV technology, and Aventis Pasteur MSD (a joint venture between Merck & Co and Aventis) are jointly developing a vaccine for the potential prophylaxis of genital warts and cervical cancer caused by human papilloma virus infection. Enrollment for a phase III trial has been completed.
Reinis
Milan
M
Academy of Sciences of the Czech Republic, Insititute of Molecular Genetics, Flemingovo nam 2, Prague 6 CZ 16637, Czech Republic. reinis@img.cas.cz
D000293:Adolescent; D000328:Adult; D000818:Animals; D002986:Clinical Trials as Topic; D003218:Condylomata Acuminata / Q000517:prevention & control; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000276:immunology*; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines; D013329:Structure-Activity Relationship; D002583:Uterine Cervical Neoplasms / Q000517:prevention & control; D014765:Viral Vaccines / Q000009:adverse effects / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use
D053918:Papillomavirus Vaccines; D014765:Viral Vaccines